Buchumschlag

Imlifidase for hematologists: Creating a therapeutic window in the presence of neutralizing alloantibodies

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Roger E. G. Schutgens
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	HemaSphere
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities
von: Milad Rasouli, et al.
Veröffentlicht: (2024)

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T‐cell lymphoblastic leukemia
von: André Almeida, et al.
Veröffentlicht: (2024)

A cellular reporter system to evaluate endogenous fetal hemoglobin induction and screen for therapeutic compounds
von: Thijs C. J. Verheul, et al.
Veröffentlicht: (2024)

The rearrangement partner and the presence of MYC mutations determine the outcome of patients with MYC and BCL6 rearrangements
von: Anna Stengel, et al.
Veröffentlicht: (2026)

PRC2‐mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7
von: Hiroyoshi Kunimoto, et al.
Veröffentlicht: (2025)

CHIC: A machine learning framework for inferring the presence of high‐risk clonal hematopoiesis using complete blood count data from 431,531 UK Biobank participants
von: William G. Dunn, et al.
Veröffentlicht: (2025)

Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (Familial Platelet Disorder with associated Myeloid Malignancy)
von: Martijn P. T. Ernst, et al.
Veröffentlicht: (2025)

Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL
von: Roger Mulet‐Lazaro, et al.
Veröffentlicht: (2025)

Overcoming a T‐ALL order: A comprehensive study linking genomics to clinical outcomes
von: Yizhou Huang, et al.
Veröffentlicht: (2024)

Sharper definitions, blurred lines: The clinical aftermath of the revised antiphospholipid syndrome criteria
von: Lauren E. Merz, et al.
Veröffentlicht: (2026)

New approaches in gene therapy for sickle cell disease, moving in vivo
von: David G. Kent
Veröffentlicht: (2024)

He shoots, he scores: Navigating the complex world of transcriptomic scores in the age of artificial intelligence
von: David G. Kent
Veröffentlicht: (2024)

Waiting and seeing: The importance of long‐term system‐wide monitoring of mouse models of disease
von: David G. Kent
Veröffentlicht: (2025)

A paradigm shift in neutrophil adverse event grading: What now?
von: Lauren E. Merz
Veröffentlicht: (2025)

Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma
von: Zoltán Kellermayer, et al.
Veröffentlicht: (2024)

Patient‐derived xenografts: Practical considerations for preclinical drug testing
von: Charles E. de Bock
Veröffentlicht: (2025)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
von: Enrico Attardi, et al.
Veröffentlicht: (2024)

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA
von: Christian M. Vonk, et al.
Veröffentlicht: (2024)

Less is more: Depleting myeloid‐biased HSCs to restore immune function
von: Hansen J. Kosasih, et al.
Veröffentlicht: (2024)

Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia
von: Hansen J. Kosasih, et al.
Veröffentlicht: (2025)

Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
von: Alberto Bavieri, et al.
Veröffentlicht: (2024)

A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax
von: Hansen J. Kosasih, et al.
Veröffentlicht: (2024)

Inhibiting the alarmin‐driven hematopoiesis‐stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis
von: Hélène F. E. Gleitz, et al.
Veröffentlicht: (2025)

CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma
von: Johannes Steinhart, et al.
Veröffentlicht: (2024)

Posttransplantation clonal dynamics of hematopoietic stem cells carrying prenatal and early‐life DNMT3A mutations
von: Lucca L. M. Derks, et al.
Veröffentlicht: (2025)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
von: Fabio Efficace, et al.
Veröffentlicht: (2024)

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype
von: Francesco Rodeghiero, et al.
Veröffentlicht: (2025)

Who owns that blood? Recontacting donors with results from genetic testing after allogeneic hematopoietic cell transplantation
von: Mirjam E. Belderbos, et al.
Veröffentlicht: (2025)

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
von: Andrew D. Zelenetz, et al.
Veröffentlicht: (2024)

Monoclonal gammopathy of undetermined significance with multiple paraproteins: A population‐based screening study
von: Sæmundur Rögnvaldsson, et al.
Veröffentlicht: (2024)

NOTCH1 fusions in pediatric T‐cell lymphoblastic lymphoma: A high‐risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
von: Emma Kroeze, et al.
Veröffentlicht: (2024)

European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet‐INNOCHRON COST Action based on a systematic evidence review
von: Francesca Fioredda, et al.
Veröffentlicht: (2025)

European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies
von: John G. Gribben, et al.
Veröffentlicht: (2025)

Medical haematology trial eligibility and the Duffy null‐associated neutrophil count: A cross‐sectional study
von: Olga Tsiamita, et al.
Veröffentlicht: (2025)

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
von: Prashant R. Tembhare, et al.
Veröffentlicht: (2024)

Obituary for a diagnosis: B‐cell prolymphocytic leukaemia (1974–2022)
von: Stephen P. Hibbs, et al.
Veröffentlicht: (2024)

“Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
von: Shoshana Burke, et al.
Veröffentlicht: (2025)

Splenectomy in β‐thalassemia patients: Practices and risks in a nationwide study
von: Audrey Benoit, et al.
Veröffentlicht: (2026)

Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
von: Lina van der Straten, et al.
Veröffentlicht: (2024)

MMS22L is a novel key actor of normal and pathological erythropoiesis
von: Elia Colin, et al.
Veröffentlicht: (2025)